#None #Boston #Scientific Advisory Board #Bambusa Therapeutics #Howard Liang

Bambusa Therapeutics Amplifies Its Leadership Team

Bambusa Therapeutics, Inc. has taken significant steps to strengthen its leadership structure by announcing the appointment of Dr. Howard Liang, Ph.D., to its Board of Directors, alongside the formation of a Scientific Advisory Board (SAB). This move marks a pivotal moment for the clinical-stage biotechnology company that focuses on pioneering next-generation bispecific antibodies aimed at addressing immunology and inflammation-related diseases.

Expertise of Dr. Howard Liang

Dr. Liang brings over 30 years of rich experience in the biotechnology sector, integrating his expertise in management, finance, and strategic planning. As the former President and CFO of Tessera Therapeutics, Dr. Liang significantly contributed to the company’s transition from a nascent platform to a formidable entity in the clinical development stage. His leadership at BeiGene is similarly noteworthy, where he played an essential role in scaling the organization from under 200 employees to a global workforce exceeding 6,000, conducting multiple successful IPOs and raising over $11 billion in capital during his tenure.

Dr. Liang's comprehensive background, which includes both corporate strategy and operational leadership, positions him to provide invaluable guidance as Bambusa Therapeutics enters its next growth phase. Dr. Shanshan Xu, the company's CEO and co-founder, expressed enthusiasm for Dr. Liang’s appointment, emphasizing the pivotal expertise he brings in biotechnology financing and strategy during this critical time for the company.

Formation of the Scientific Advisory Board

Alongside Dr. Liang’s appointment, Bambusa Therapeutics is establishing a Scientific Advisory Board to aid in navigating the complexities of drug development. This board consists of leaders recognized globally in the fields of biopharmaceuticals, dermatology, and respiratory medicine. Key members of the SAB include:

• - Stefan Oschmann, DVM - The former Chairman and CEO of Merck KGaA, who possesses decades of leadership experience in biopharmaceuticals.
• - Eric Simpson, M.D. - A respected Professor of Dermatology at Oregon Health & Science University, known for his expertise in atopic dermatitis and chronic inflammatory skin disorders.
• - Ian Pavord, D.M. - A Professor of Respiratory Medicine at the University of Oxford, recognized for his contributions to the treatment of airway inflammation, which has been instrumental in the development of biologic therapies for diseases like severe asthma and COPD.

Dr. Thang Ho, Chief Development Officer at Bambusa Therapeutics, stated, "The caliber of these advisors reflects our ambitious vision in addressing complex medical conditions with our scientific innovations." Their diverse expertise is expected to sharpen Bambusa’s strategic focus as it moves forward with developing its innovative pipeline.

The Future of Bambusa Therapeutics

Bambusa’s vision centers on delivering breakthrough treatments for patients suffering from chronic conditions related to immunology and inflammation. Their bispecific antibody platform leverages advanced engineering techniques and innovative delivery methods to enhance therapeutic outcomes. Some products in development include:

• - BBT001: Targeting IL-4Rα and IL-31, it is currently undergoing Phase 1b/2a trials for treating atopic dermatitis and chronic spontaneous urticaria.
• - BBT002: Focusing on IL-4Rα and IL-5, it is likewise in Phase 1b/2a development for Type 2 inflammatory disorders such as COPD and chronic rhinosinusitis with nasal polyps.
• - BBT003 and BBT004: These are currently in preclinical stages aimed at addressing various autoantibody-driven autoimmune diseases and gastrointestinal health.

As Bambusa Therapeutics builds its reputation as a leader in immunotherapy, the integration of Dr. Liang and the formation of a knowledgeable advisory board exemplify its commitment to realizing its goals and better serving patients in need of effective medicinal solutions.

For more information regarding Bambusa Therapeutics and its ongoing projects, visit their website www.bambusatx.com.